ROS1 and non-small cell lung carcinoma: The phase II AcSé study of crizotinib in patients with MET- or ROS1-positive NSCLC showed that the ORR was 16% in patients with MET copy number ≥ 6, and 10.7% in patients with MET mutation [23].